{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T15:40:14Z","timestamp":1714059614511},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2001,9,11]],"date-time":"2001-09-11T00:00:00Z","timestamp":1000166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,9,11]],"date-time":"2001-09-11T00:00:00Z","timestamp":1000166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/cvm-2-5-233","type":"journal-article","created":{"date-parts":[[2002,9,26]],"date-time":"2002-09-26T12:07:27Z","timestamp":1033042047000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Arterial indications for the low molecular weight heparins"],"prefix":"10.1186","volume":"2","author":[{"given":"Walter","family":"Ageno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menno V","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2001,9,11]]},"reference":[{"key":"77_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S0146-2806(96)80004-1","volume":"21","author":"PA Ribeiro","year":"1996","unstructured":"Ribeiro PA, Shah PM: Unstable angina: new insights into pathophysiologic characteristics, prognosis, and management strategies. Curr Probl Cardiol. 1996, 21: 669-732.","journal-title":"Curr Probl Cardiol"},{"key":"77_CR2","doi-asserted-by":"publisher","first-page":"2B","DOI":"10.1016\/0002-9149(91)90378-X","volume":"68","author":"JH Chesebro","year":"1991","unstructured":"Chesebro JH, Zoldhelyi P, Fuster V: Pathogenesis of thrombosis in unstable angina. Am J Cardiol. 1991, 68: 2B-10B.","journal-title":"Am J Cardiol"},{"key":"77_CR3","doi-asserted-by":"publisher","first-page":"9C","DOI":"10.1016\/0002-9149(91)90218-A","volume":"68","author":"JH Chesebro","year":"1991","unstructured":"Chesebro JH, Zoldhelyi P, Fuster V: Plaque disruption and thrombosis in unstable angina pectoris. Am J Cardiol. 1991, 68: 9C-15C.","journal-title":"Am J Cardiol"},{"key":"77_CR4","doi-asserted-by":"publisher","first-page":"611S","DOI":"10.1378\/chest.114.5_Supplement.611S","volume":"114","author":"JA Cairns","year":"1998","unstructured":"Cairns JA, Th\u00e9roux P, Lewis HD, Ezekowitz M, Meade TW, Sutton GC: Antithrombotic agents in coronary artery disease. Chest. 1998, 114: 611S-633S.","journal-title":"Chest"},{"key":"77_CR5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1056\/NEJM198308183090703","volume":"309","author":"HD Lewis Jr","year":"1983","unstructured":"Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983, 309: 396-403.","journal-title":"N Engl J Med"},{"key":"77_CR6","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","volume":"313","author":"JA Cairns","year":"1985","unstructured":"Cairns JA, Gent M, Singer J, Finnie KH, Froggatt GM, Holder DA, Jablonsky G, Kostuk WJ, Melendez LJ, Myers MG: Aspirin, sulphynpirazone or both in unstable angina: Results of a Veterans Administration Cooperative Study. N Engl J Med. 1985, 313: 1369-1375.","journal-title":"N Engl J Med"},{"key":"77_CR7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","volume":"319","author":"P Theroux","year":"1988","unstructured":"Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pel-letier E, Juneau M, Stasiak J, deGuise P: Aspirin, heparin or both to treat acute unstable angina. N Engl J Med. 1988, 319: 1105-1111.","journal-title":"N Engl J Med"},{"key":"77_CR8","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","volume":"336","author":"The RISC Group","year":"1990","unstructured":"The RISC Group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990, 336: 827-830. 10.1016\/0140-6736(90)92336-G.","journal-title":"Lancet"},{"key":"77_CR9","first-page":"349","volume":"2","author":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","year":"1988","unstructured":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988, 2: 349-360.","journal-title":"Lancet"},{"key":"77_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/bmj.308.6923.235","volume":"308","author":"Antiplatelet Trialists Collaboration","year":"1994","unstructured":"Antiplatelet Trialists Collaboration: Collaborative overview of randomized trials of antiplatelet treatment, I: prevention of vascular death, MI, and stroke by prolonged antiplatelet therapy in different categories of patients. Br Med J. 1994, 308: 235-246.","journal-title":"Br Med J"},{"key":"77_CR11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/s-0038-1657528","volume":"78","author":"F Van de Werf","year":"1997","unstructured":"Van de Werf F: Clinical trials with glycoprotein IIb\/IIIa receptor antagonists in acute coronary syndromes. Thromb Haemost. 1997, 78: 210-213.","journal-title":"Thromb Haemost"},{"key":"77_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","volume":"276","author":"A Oler","year":"1996","unstructured":"Oler A, Whooley MA, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996, 276: 811-815. 10.1001\/jama.276.10.811.","journal-title":"JAMA"},{"key":"77_CR13","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199105303242206","volume":"324","author":"J Hirsh","year":"1991","unstructured":"Hirsh J: Heparin. N Engl J Med. 1991, 324: 1565-1574.","journal-title":"N Engl J Med"},{"key":"77_CR14","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1161\/01.CIR.89.3.1449","volume":"89","author":"J Hirsh","year":"1994","unstructured":"Hirsh J, Fuster V: Guide to anticoagulant therapy, Part 1: Heparin. Circulation. 1994, 89: 1449-1480.","journal-title":"Circulation"},{"key":"77_CR15","doi-asserted-by":"publisher","first-page":"489S","DOI":"10.1378\/chest.114.5_Supplement.489S","volume":"114","author":"J Hirsh","year":"1998","unstructured":"Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman Em, Dalen JE: Heparin and low molecular weight heparin. Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998, 114: 489S-510S.","journal-title":"Chest"},{"key":"77_CR16","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","volume":"332","author":"TE Warkentin","year":"1995","unstructured":"Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Tech M, Gent M, Kelton JG: Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med. 1995, 332: 1330-1335. 10.1056\/NEJM199505183322003.","journal-title":"N Engl J Med"},{"key":"77_CR17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1056\/NEJM199709043371007","volume":"337","author":"JI Weitz","year":"1997","unstructured":"Weitz JI: Drug Therapy: Low molecular weight heparins. N Engl J Med. 1997, 337: 688-698. 10.1056\/NEJM199709043371007.","journal-title":"N Engl J Med"},{"key":"77_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0049-3848(84)90265-2","volume":"35","author":"JF Cade","year":"1984","unstructured":"Cade JF, Buchanan MR, Boneu B, Ockelford P, Cater CJ, Cerskus AL, Hirsh J: A comparison of the antithrombotic and hemorrhagic effects of low molecular weight heparins fractions. The influence of the method of preparation. Thromb Res. 1984, 35: 613-625.","journal-title":"Thromb Res"},{"key":"77_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0735-1097(95)80001-W","volume":"26","author":"EP Gurfinkel","year":"1995","unstructured":"Gurfinkel EP, Eustaquio JM, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Daroca AM, Mautner B: Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 1995, 26: 313-318. 10.1016\/0735-1097(95)80001-W.","journal-title":"J Am Coll Cardiol"},{"key":"77_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","volume":"347","author":"Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group","year":"1996","unstructured":"Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group: Low molecular weight heparin during instability in coronary artery disease. Lancet. 1996, 347: 561-568.","journal-title":"Lancet"},{"key":"77_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","volume":"90","author":"PA Merlini","year":"1994","unstructured":"Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD: Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994, 90: 61-68.","journal-title":"Circulation"},{"key":"77_CR22","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1161\/01.CIR.91.10.2520","volume":"91","author":"HM Hoffmeister","year":"1995","unstructured":"Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L: Alterations of coagulation and fibrinolytic and kallikrein-kinin system in the acute and postacute phases in patients with unstable angina. Circulation. 1995, 91: 2520-2527.","journal-title":"Circulation"},{"key":"77_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/01.CIR.96.1.61","volume":"96","author":"W Klein","year":"1997","unstructured":"Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, van der Meer J, Olaisson E, Undeland S, Ludwig K: Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation. 1997, 96: 61-68.","journal-title":"Circulation"},{"key":"77_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJM199708143370702","volume":"337","author":"M Cohen","year":"1997","unstructured":"Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F: A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997, 337: 447-452. 10.1056\/NEJM199708143370702.","journal-title":"N Engl J Med"},{"key":"77_CR25","first-page":"122F","volume":"14(suppl F)","author":"S Goodman","year":"1998","unstructured":"Goodman S, Langer A, Demers C, Turpie AGG, Bigonzi F, Radley D, Lelouer V, Gosset F, Fromell G, Cohen M: One year follow-up of the ESSENCE trial (enoxaparin vs heparin in unstable angina\/non-Q-wave myocardial infarction): sustained clinical benefit [abstract]. Can J Cardiol. 1998, 14(suppl F): 122F-","journal-title":"Can J Cardiol"},{"key":"77_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S0140-6736(99)07350-X","volume":"354","author":"FRISC II investigators","year":"1999","unstructured":"FRISC II investigators: Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicenter study. Lancet. 1999, 354: 701-707. 10.1016\/S0140-6736(99)07350-X.","journal-title":"Lancet"},{"key":"77_CR27","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","volume":"100","author":"EM Antman","year":"1999","unstructured":"Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Prem-mereur J, Braunwald E: Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11b trial. Circulation. 1999, 100: 1593-1601.","journal-title":"Circulation"},{"key":"77_CR28","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1053\/euhj.1999.1879","volume":"20","author":"FRAXIS Study Group","year":"1999","unstructured":"FRAXIS Study Group: Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic Syndrome). Eur Heart J. 1999, 20: 1553-1562. 10.1053\/euhj.1999.1879.","journal-title":"Eur Heart J"},{"key":"77_CR29","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S0735-1097(97)00258-1","volume":"30","author":"F Kontny","year":"1997","unstructured":"Kontny F, Dale J, Abildgaard U, Pedersen TR: Randomized trial of low molecular weight heparin (Dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction. The Fragmin in Acute Myocardial Infarction (FRAMI) study. J Am Coll Cardiol. 1997, 30: 962-969. 10.1016\/S0735-1097(97)00258-1.","journal-title":"J Am Coll Cardiol"},{"key":"77_CR30","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0002-9149(96)00152-X","volume":"77","author":"A Glick","year":"1996","unstructured":"Glick A, Kornowsky R, Michowich Y, Koifman B, Roth A, Laniado S, Keren G: Reduction of reinfarction and angina with use of low molecular weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol. 1996, 77: 1145-1148. 10.1016\/S0002-9149(96)00152-X.","journal-title":"Am J Cardiol"},{"key":"77_CR31","doi-asserted-by":"publisher","first-page":"228S","DOI":"10.1378\/chest.119.1_suppl.228S","volume":"119(suppl 1)","author":"JA Cairns","year":"2001","unstructured":"Cairns JA, Th\u00e9roux P, Lewis HD, Ezekowitz M, Meade TW: Antithrombotic agents in coronary artery disease. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 2001, 119(suppl 1): 228S-252S. 10.1378\/chest.119.1_suppl.228S.","journal-title":"Chest"},{"key":"77_CR32","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1053\/euhj.2000.2301","volume":"21","author":"ME Bertrand","year":"2000","unstructured":"Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W: Management of acute coronary syndromes without persistent ST segment elevation. Recommendation of the Task Force of the European Society of Cardiology. Eur Heart J. 2000, 21: 1406-1432. 10.1053\/euhj.2000.2301.","journal-title":"Eur Heart J"},{"key":"77_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0735-1097(96)00447-0","volume":"29","author":"B Lindahl","year":"1997","unstructured":"Lindahl B, Venge P, Wallentin L: Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol. 1997, 29: 43-48. 10.1016\/S0735-1097(96)00447-0.","journal-title":"J Am Coll Cardiol"},{"key":"77_CR34","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/01.CIR.98.4.294","volume":"98","author":"G Montalescot","year":"1998","unstructured":"Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP, Bigonzi F, Thomas D: Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease. Beneficial effect of enoxaparin. Circulation. 1998, 98: 294-299.","journal-title":"Circulation"},{"key":"77_CR35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJM199501263320408","volume":"332","author":"HJM Barbett","year":"1995","unstructured":"Barbett HJM, Eliasziw M, Meldrum HE: Drugs and surgery in the prevention of ischemic stroke. N Engl J Med. 1995, 332: 238-248. 10.1056\/NEJM199501263320408.","journal-title":"N Engl J Med"},{"key":"77_CR36","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1161\/01.STR.25.9.1901","volume":"25","author":"HP Adams Jr","year":"1994","unstructured":"Adams HP, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marler JR, Woolson RF, Zivin JA: Guidelines for the management of patients with acute ischameic stroke: a statement for healthcare professionals from a special writing group of the Stroke Council, Amercian Heart Foundation. Stroke. 1994, 25: 1901-1914.","journal-title":"Stroke"},{"key":"77_CR37","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1136\/bmj.321.7274.1455","volume":"321","author":"G Gubitz","year":"2000","unstructured":"Gubitz G, Sandercock P: Prevention of ischaemic stroke. BMJ. 2000, 321: 1455-1459. 10.1136\/bmj.321.7274.1455.","journal-title":"BMJ"},{"key":"77_CR38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1161\/01.STR.19.3.403","volume":"19","author":"VT Miller","year":"1988","unstructured":"Miller VT, Hart RG: Heparin anticoagulation in acute brain ischemia. Stroke. 1988, 19: 403-406.","journal-title":"Stroke"},{"key":"77_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1161\/01.STR.20.2.173","volume":"20","author":"P Scheinberg","year":"1989","unstructured":"Scheinberg P: Heparin anticoagulation. Stroke. 1989, 20: 173-174.","journal-title":"Stroke"},{"key":"77_CR40","doi-asserted-by":"publisher","first-page":"885","DOI":"10.7326\/0003-4819-115-11-885","volume":"115","author":"JF Rothrock","year":"1991","unstructured":"Rothrock JF, Hart RG: Antithrombotic therapy in cerebrovascu-lar disease. Ann Int Med. 1991, 115: 885-895.","journal-title":"Ann Int Med"},{"key":"77_CR41","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","volume":"349","author":"International Stroke Trial Collaborative Group","year":"1997","unstructured":"International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet. 1997, 349: 1569-1581. 10.1016\/S0140-6736(97)04011-7.","journal-title":"Lancet"},{"key":"77_CR42","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","volume":"333","author":"The National Institute of Neurological Disorders and stroke rt-PA Stroke Study Group","year":"1995","unstructured":"The National Institute of Neurological Disorders and stroke rt-PA Stroke Study Group: NINDS trial. N Engl J Med. 1995, 333: 1581-1587. 10.1056\/NEJM199512143332401.","journal-title":"N Engl J Med"},{"key":"77_CR43","first-page":"1711","volume":"27","author":"HP Adams Jr","year":"1996","unstructured":"Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M, Thies W: Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke \u2013 A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke. 1996, 27: 1711-1718.","journal-title":"Stroke"},{"key":"77_CR44","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1056\/NEJM199512143332402","volume":"333","author":"R Kay","year":"1995","unstructured":"Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, Chan FL, Fong KY, Law CB, Wong A, Woo J: Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995, 333: 1588-1593. 10.1056\/NEJM199512143332402.","journal-title":"N Engl J Med"},{"key":"77_CR45","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1001\/jama.279.16.1265","volume":"279","author":"The Publicatons Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators","year":"1998","unstructured":"The Publicatons Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators: Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomised controlled trial. JAMA. 1998, 279: 1265-1272.","journal-title":"JAMA"},{"key":"77_CR46","first-page":"1","volume":"8 (suppl 4)","author":"M Hommel","year":"1998","unstructured":"Hommel M: FISS bis Investigators Group. Fraxiparine in Stroke Study (FISS bis) [abstract]. Cerebrovasc Dis. 1998, 8 (suppl 4): 1-103.","journal-title":"Cerebrovasc Dis"},{"key":"77_CR47","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0140-6736(00)02085-7","volume":"355","author":"E Berge","year":"2000","unstructured":"Berge E, Abdelnoor M, Nakstad PH, Sandset PM: Low molecular weight heparin versus aspirin in patients with acute iscaemic stroke and atrial fibrillation: a double-blind randomised study. Lancet. 2000, 355: 1205-1210. 10.1016\/S0140-6736(00)02085-7.","journal-title":"Lancet"},{"key":"77_CR48","volume-title":"In The Cochrane Library, Issue 2. Oxford: Update Software;","author":"G Gubitz","year":"1999","unstructured":"Gubitz G, Sandercock P, Counsell C, Signorini D: Anticoagulants for acute ischaemic stroke (Cochrane Review). In The Cochrane Library, Issue 2. Oxford: Update Software;. 1999"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cvm-2-5-233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/cvm-2-5-233\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cvm-2-5-233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T15:04:35Z","timestamp":1714057475000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/cvm-2-5-233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9,11]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2001,10]]}},"alternative-id":["77"],"URL":"https:\/\/doi.org\/10.1186\/cvm-2-5-233","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9,11]]},"assertion":[{"value":"11 September 2001","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"233"}}